Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;259(7):1965-1974.
doi: 10.1007/s00417-021-05144-w. Epub 2021 Mar 8.

Deep sclerectomy and trabeculectomy augmented with Mitomycin C: 2-year post-operative outcomes

Rahul Dwivedi  1 , Tobi Somerville  2 , Robert Cheeseman  2 , Clare Rogers  2 , Mark Batterbury  2 , Anshoo Choudhary  2
Affiliations

Deep sclerectomy and trabeculectomy augmented with Mitomycin C: 2-year post-operative outcomes

Rahul Dwivedi et al. Graefes Arch Clin Exp Ophthalmol. 2021 Jul.

Abstract

Purpose: Two-year post-operative outcomes of both deep sclerectomy (DS) and trabeculectomy surgery (Trab) augmented with Mitomycin C (MMC) at a single tertiary eye centre.

Methods: Retrospective review of DS + MMC and trabeculectomy + MMC at a single centre between February 2015 and March 2018. Patients with a minimum of 12-month follow-up were included. Post-operative follow-up: day 1, week 1, months 1/3/6/12/18/24. Primary outcomes: changes in intraocular pressure (IOP) and changes in LogMAR visual acuity (BCVA) pre- and post-procedure.

Secondary outcomes: changes in number of eye drops, number of follow-up clinic visits, post-operative complications and further surgical interventions. Complete success: IOP ≤ 21 mmHg off all IOP-lowering medications. Qualified success: IOP ≤ 21 mmHg on medication. Failure: IOP > 21 mmHg at 24 months or ≤ 5 mmHg on 2 consecutive follow-up visits after 3 months +/- additional incisional glaucoma surgery +/- loss of light perception. Statistical analysis performed using Microsoft Excel + SPSS.

Results: 90 eyes: DS + MMC = 46 eyes, Trab + MMC = 44 eyes. DS + MMC v Trab + MMC: mean pre-op IOP = 19.57 mmHg v 18.89 mmHg, significantly reduced at all post-operative time-points for both groups (p < 0.001). Mean IOP reduction from baseline = 33.94% v 38.39%; > 30% IOP reduction = 54.35% v 68.18%. IOP ≤ 16 mmHg = 82.61% (38/46) v 95.46% (42/44), IOP ≤ 12 mmHg = 52.17% (24/46) v 72.72% (32/44). Complete success = 67.39% v 61.36%, qualified success = 26.09% v 29.55%, failure = 6.52% v 9.09%. Post-op BCVA: no statistically significant differences between two groups (p = 0.09). Mean pre-op drops v post-op drops = 2.98 v 0.38 (DS + MMC; p < 0.001); 2.68 v 0.39 (Trab + MMC; p < 0.001). Further surgical intervention = 13% v 29.55%. Mean number of post-op clinic visits DS + MMC v Trab + MMC = 10.09 v 13.02 (p = 0.005).

Conclusion: Both procedures achieve sustained intraocular pressure and drop reduction at 2 years post-op. DS + MMC has lower complication rates requiring less intervention and significantly fewer clinic visits, which may be an important factor for deciding surgical management of glaucoma patients in the era of Covid-19 to reduce patient/clinician exposure to the virus.

Keywords: Deep sclerectomy; Glaucoma; Mitomycin C; Trabeculectomy.

PubMed Disclaimer

Conflict of interest statement

None of the authors have any competing or financial interests in this work. All authors have contributed significantly and are in agreement with the content of the manuscript.

Figures

Fig. 1
Fig. 1
(Microsoft Excel) A graph comparing mean post-operative intraocular pressure (IOP) between trabeculectomy and deep sclerectomy augmented with MMC
Fig. 2
Fig. 2
(SPSS) Kaplan-Meier survival plots outlining cumulative success until 24 months for both groups
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–2090. doi: 10.1016/j.ophtha.2014.05.013. - DOI - PubMed
    1. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, Early Manifest Glaucoma Trial Group Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma Trial. Arch Ophthalmol. Oct. 2002;120(10):1268–1279. - PubMed
    1. National Institute for Health and Care Excellence (2017) Glaucoma: diagnosis and management (NICE Guideline NG81). Available at https://www.nice.org.uk/guidance/ng81. Accessed 15th October 2020. - PubMed
    1. Khaw PT, Sherwood MB, MacKay SL, Rossi MJ, Schultz G. Five- minute treatments with fluorouracil, floxuridine, and mitomycin have long-term effects on human Tenon's capsule fibroblasts. Arch Ophthalmol. 1992;110(8):1150–1154. doi: 10.1001/archopht.1992.01080200130040. - DOI - PubMed
    1. Wilkins M, Indar A, Wormald R. Intra-operative mitomycin C for glaucoma surgery. Cochrane Database Syst Rev. 2005;19(4):CD002897. - PMC - PubMed